Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China
Authors:
Open Access
- 3 May 2024
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (5) , e29640
Abstract
After the termination of zero‐COVID‐19 policy, the populace in China has experienced both Omicron BA.5 and XBB waves. Considering the poor antibody responses and severe outcomes observed among the elderly following infection, we conducted a longitudinal investigation to examine the epidemiological characteristics and antibody kinetics among 107 boosted elderly participants following the Omicron BA.5 and XBB waves. We observed that 96 participants (89.7%) were infected with Omicron BA.5, while 59 (55.1%) participants were infected with Omicron XBB. Notably, 52 participants (48.6%) experienced dual infections of both Omicron BA.5 and XBB. The proportion of symptomatic cases appeared to decrease following the XBB wave (18.6%) compared to that after the BA.5 wave (59.3%). Omicron BA.5 breakthrough infection induced lower neutralizing antibody titers against XBB.1.5, BA.2.86, and JN.1, while reinfection with Omicron XBB broadened the antibody responses against all measured Omicron subvariants and may alleviate the wild type‐vaccination induced immune imprinting. Boosted vaccination type and comorbidities were the significant factors associated with antibody responses. Updated vaccines based on emerging severe acute respiratory syndrome coronavirus 2 variants are needed to control the Coronavirus Disease 2019 pandemic in the elderly.Keywords
Funding Information
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
This publication has 46 references indexed in Scilit:
- Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfectionJournal of Infection, 2023
- Continued evasion of neutralizing antibody response by Omicron XBB.1.16Cell Reports, 2023
- SARS-CoV-2–specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022Journal of Infection, 2023
- Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfectionThe Lancet Regional Health - Western Pacific, 2023
- Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional studyEBioMedicine, 2023
- Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative reviewClinical Microbiology and Infection, 2021
- Safety and effectiveness of SARS‐CoV‐2 vaccines: A systematic review and meta‐analysisJournal of Medical Virology, 2021
- Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19)JAMA Pediatrics, 2020
- SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomesGeroScience, 2020
- Age‐related rhesus macaque models of COVID‐19Animal Models and Experimental Medicine, 2020